NCT03454724 - Study of MeRes100 in the Treatment of Patient With Coronary Artery Disease. | Biotech Hunter

Enrollment

484

Participants

Timeline

Start Date

January 1, 2020

Primary Completion Date

December 1, 2020

Study Completion Date

December 1, 2024

Conditions

Coronary Artery Disease

Interventions

DEVICE

MeRes100 Sirolimus-Eluting BioResorbable Vascular Scaffold System

MeRes100 Sirolimus-Eluting BioResorbable Vascular Scaffold System used in the treatment of patients with coronary artery disease along with standard percutaneous angioplasty procedure.

DEVICE

Xience EES Everolimus Eluting Coronary Stent System

Xience EES Everolimus Eluting Coronary Stent System indicated for the treatment of coronary artery disease along with standard percutaneous angioplasty procedure.